Potential new targets for antimalarial chemotherapy include parasite proteases, which are required for several cellular functions during the Plasmodium falciparum life cycle. Four new derivatives of N-alkyl and N-benzyl-1,10-phenanthroline have been synthesized. Those are (1)-N-methyl-1,10-phenanthrolinium sulfate, (1)-N-ethyl-1,10-phenanthrolinium sulfate, (1)-N-benzyl-1,10-phenanthrolinium chloride, and (1)-N-benzyl-1,10-phenanthrolinium iodide. Those compounds had potential antiplasmodial activity with IC50 values from 260.42 to 465.38 nM. Cysteine proteinase inhibitor E64 was used to investigate the mechanism of action of N-alkyl and N-benzyl-1,10-phenanthroline derivatives. A modified fixed-ratio isobologram method was used to study the in vitro interactions between the new compounds with either E64 or chloroquine. The interaction between N-alkyl and N-benzyl-1,10-phenanthroline derivatives and E64 was additive as well as their interactions with chloroquine were also additive. Antimalarial mechanism of chloroquine is mainly on the inhibition of hemozoin formation. As the interaction of chloroquine and E64 was additive, the results indicated that these new compounds had a mechanism of action by inhibiting Plasmodium proteases. 1. Introduction The erythrocytic life cycle of Plasmodium, which is responsible for all clinical manifestations of malaria, begins when free merozoites invade erythrocytes. The intraerythrocytic parasites develop from small ring-stage organisms to larger, more metabolically active trophozoites and then to multinucleated schizonts. The erythrocytic cycle is completed when mature schizonts rupture erythrocytes, releasing numerous invasive merozoites. Proteases appear to be required for cleavage of red blood cell ankyrin to facilitate host cell rupture and subsequent reinvasion of erythrocytes by merozoites, and for the degradation of hemoglobin ingested by intraerythrocytic trophozoites [1, 2]. Extensive evidence suggest that the degradation of hemoglobin is necessary for the growth of erythrocytic malaria parasite, apparently to provide free amino acids for parasite protein synthesis [3, 4]. In P. falciparum, hemoglobin degradation occurs predominantly in trophozoites and early schizonts, the stages at which the parasites are most metabolically active. Trophozoite ingest erythrocyte cytoplasm and transport it to a large central food vacuole. In the food vacuole, intact heme is released from hemoglobin to form the major component of malarial hemozoin pigment [5]. The food vacuole appears to be the site of action of a number of
References
[1]
P. J. Rosenthal, “Proteases of malaria parasites: new targets for chemotherapy,” Emerging Infectious Diseases, vol. 4, no. 1, pp. 49–57, 1998.
[2]
D. C. Greenbaum, A. Baruch, and A. Baruch, “A role for the protease falcipain 1 in host cell invasion by the human malaria parasite,” Science, vol. 298, no. 5600, pp. 2002–2006, 2002.
[3]
J. H. McKerrow, E. Sun, P. J. Rosenthal, and J. Bouvier, “The proteases and pathogenicity of parasitic protozoa,” Annual Review of Microbiology, vol. 47, pp. 821–853, 1993.
[4]
P. J. Rosenthal and S. R. Meshnick, “Hemoglobin catabolism and iron utilization by malaria parasites,” Molecular and Biochemical Parasitology, vol. 83, no. 2, pp. 131–139, 1996.
[5]
A. F. G. Slater, “Malaria pigment,” Experimental Parasitology, vol. 74, no. 3, pp. 362–365, 1992.
[6]
P. J. Rosenthal, “Review: antimalarial drug discovery: old and new approaches,” Journal of Experimental Biology, vol. 206, no. 21, pp. 3735–3744, 2003.
[7]
M. Mungthin, P. G. Bray, R. G. Ridley, and S. A. Ward, “Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 11, pp. 2973–2977, 1998.
[8]
A. Semenov, J. E. Olson, and P. J. Rosenthal, “Antimalarial synergy of cysteine and aspartic protease inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 9, pp. 2254–2258, 1998.
[9]
A. D. Yapi, M. Mustofa, and M. Mustofa, “New potential antimalarial agents: synthesis and biological activities of original diaza-analogs of phenanthrene,” Chemical and Pharmaceutical Bulletin, vol. 48, no. 12, pp. 1886–1889, 2000.
[10]
Mustofa, A. D. Yapi, A. Valentin, and I. Tahir, “In vitro antiplasmodial activity of 1,10-phenanthroline derivatives and its quantitative stucture-activity relationship,” Berkala Ilmu Kedokteran, vol. 35, no. 2, pp. 67–74, 2003.
[11]
E. N. Sholikhah, Supargiyono, Jumina, M. A. Wijayanti, I. Tahir, R. Hadanu, and Mustofa, “In vitro antiplasmodial activity and cytotoxicity of newly synthesized N-alkyl and N-benzyl-1,10-phenanthroline derivatives,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 37, no. 6, pp. 1072–1077, 2006.
[12]
M. A. Wijayanti, E. N. Sholikhah, I. Tahir, R. Hadanu, Jumina, Supargiyono, and Mustofa, “Antiplasmodial activity and acute toxicity of N-alkyl and N-benzyl-1,10-phenanthroline derivatives in mouse malaria model,” Journal of Health Science, vol. 52, no. 6, pp. 794–799, 2006.
[13]
M. A. Wijayanti, E. N. Sholikhah, I. Tahir, R. Hadanu, Jumina, Supargiyono, and Mustofa, “Heme polymerization inhibition activity (HPIA) of N-alkyl and N-benzyl-1,10-phenanthroline derivatives as antimalaria,” in Proceeding of International Conference on Chemical Science (ICCS '07), 2007.
[14]
Mustofa, Jumina, M. A. Wijayanti, I. Tahir, and E. N. Sholikhah, “Development of new 1,10-phenantroline derivatives as antimalaria,” Final Report, The Integrated Excellent Research from Ministry of Research and Technology, Indonesia, 2005.
[15]
R. Hadanu, S. Mastje, Jumina, et al., “Quantitative structure-activity relationship analysis (QSAR) of antimalarial 1,10-phenantroline derivatives compounds,” Indian Journal of Chemistry, vol. 7, no. 1, pp. 72–77, 2007.
[16]
W. Trager and J. B. Jensen, “Human malaria parasites in continuous culture,” Science, vol. 193, no. 4254, pp. 673–675, 1976.
[17]
C. E. Contreras, M. A. Rivas, J. Domínguez, J. Charris, M. Palacios, N. E. Bianco, and I. Blanca, “Stage-specific activity of potential antimalarial compounds measured in vitro by flow cytometry in comparison to optical microscopy and hypoxanthine uptake,” Memorias do Instituto Oswaldo Cruz, vol. 99, no. 2, pp. 179–184, 2004.
[18]
M. Lebbad, “Estimation of the percentage of erythrocytes infected with Plasmodium falciparum in a thin blood film,” in Methos in Malaria Research, Manassas, Va, USA, ATCC, 2004.
[19]
J. Wiesner, D. Henschker, D. B. Hutchinson, E. Beck, and H. Jomaa, “In vitro and Min vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 9, pp. 2889–2894, 2002.
[20]
L. Zhao, M. G. Wientjes, and J. L.-S. Au, “Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses,” Clinical Cancer Research, vol. 10, no. 23, pp. 7994–8004, 2004.
[21]
K. Pattanapanyasat, K. Kotipun, K. Yongvanitchit, R. C. Hider, D. E. Kyle, D. G. Heppner, and D. S. Walsh, “Effects of hydroxypyridinone iron chelators in combination with antimalarial drugs on the in vitro growth of Plasmodium falciparum,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 32, no. 1, pp. 64–69, 2001.
[22]
Q. L. Fivelman, I. S. Adagu, and D. C. Warhurst, “Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 11, pp. 4097–4102, 2004.